Rasagiline tablets, developed by Teva, are approved in more than 40 countries for the treatment of PD. Teva received its first approval in 2005 in Israel and Europe
The EC approval makes RoACTEMRA the first anti IL-6 receptor biologic available as subcutaneous and intravenous (IV) formulations for both monotherapy and combination therapy with methotrexate (MTX). The
Incruse is a once-daily long-acting muscarinic antagonist (LAMA), a type of bronchodilator also known as an anticholinergic. Currently licensed across all EU member states, Incruse is a 55mcg
A full analysis of the trial’s results is scheduled to be completed in the third quarter of 2014, but preliminary data suggests that GM604 shows significant promise for
Nexavar is co-developed by Onyx Pharmaceuticals, an Amgen subsidiary, and Bayer HealthCare Pharmaceuticals, except in Japan where Bayer manages all development. In November 2013, the European Commission (EC)
Trametinib as a single agent has not showed clinical activity in patients who have progressed on a prior BRAF inhibitor therapy. According to the company, before taking trametinib,
Initial focus in the deal for SNBL is to promote Crown Bioscience services to its Japanese clients, in doing so extending SNBL’s service offering. Under the deal, SNBL
The new drug uses Novozymes’ Veltis technology to achieve an extended half-life that means patients are only required to inject their medication once a week. The approval follows
The trail met its primary objective and the once-daily Onbrez Breezhaler (indacaterol) 150mcg showed non-inferiority in lung function at week 12 to twice-daily Seretide (salmeterol/fluticasone propionate (SFC)) 50/500mcg
The CHMP positive opinion follows recent US FDA approval of the drug for treatment of and reduction in the risk of recurrent DVT and PE. Both DVT and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.